Alkermes' Top Management Takes Its Transformative Message On The Road
This article was originally published in The Pink Sheet Daily
Executive Summary
Five commercial products, led by long-acting anti-psychotics, will drive growth through 2015, when the new pipeline will start to contribute, management says.
You may also be interested in...
Alkermes After Elan: A Slow Start But A Maturing Pipeline
As it continues its transformation into a drug development company, Alkermes says it is meeting its own expectations, but analysts are disappointed, at least in the short term.
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
Extensive data on immediate and extended release exenatide can be "leveraged and applied" to speed development of a once-monthly injectable, which is ready for Phase III.
Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes
Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.